Similar Efficacy and Safety of Basaglar® and Lantus® in Patients with Type 2 Diabetes in Age Groups (< 65 Years, ≥ 65 Years): A Post Hoc Analysis from the ELEMENT-2 Study-Reference-Cited by-同舟云学术

Similar Efficacy and Safety of Basaglar® and Lantus® in Patients with Type 2 Diabetes in Age Groups (< 65 Years, ≥ 65 Years): A Post Hoc Analysis from the ELEMENT-2 Study

Published:2018-03-14 Issue:2 Volume:9 Page:827-837
ISSN:1869-6953
Container-title:Diabetes Therapy
language:en
Short-container-title:Diabetes Ther

Author:

Pollom Robyn K.,Costigan Timothy,Lacaya Lyndon B.,Ilag Liza L.,Hollander Priscilla A.

Funder

Eli Lilly and Company

Boehringer Ingelheim

Publisher

Springer Science and Business Media LLC

Subject

Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

http://link.springer.com/content/pdf/10.1007/s13300-018-0405-5.pdf

Reference22 articles.

1. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes. Estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27:1047–53.

2. American Diabetes Association. Standards of medical care in diabetes, older adults. Diabetes Care. 2016;39(Suppl 1):S81–5.

3. Ligthelm RJ, Kaiser M, Vora J, Yale JF. Insulin use in elderly adults: risk of hypoglycemia and strategies for care. J Am Geriatr Soc. 2012;60:1564–70.

4. Kirkman MS, Briscoe VJ, Clark N, et al. Diabetes in older adults: a consensus report. Diabetes Care. 2012;35:2650–64.

5. International Diabetes Federation. IDF global guideline for managing older people with type 2 diabetes. 2013. https://www.idf.org/our-activities/advocacy-awareness/resources-and-tools/78:global-guideline-for-managing-older-people-with-type-2-diabetes.html . Accessed 29 Nov 2017.

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. An exploratory analysis of the cost‐effectiveness of insulin glargine 300 units/mL versus insulin glargine 100 units/mL over a lifetime horizon using the BRAVO diabetes model;Diabetic Medicine;2024-03-12

2. Injectable systems for long-lasting insulin therapy;Advanced Drug Delivery Reviews;2023-12

3. Immunogenicity and Efficacy of Insulin Glargine Biosimilar Ezelin versus Originator Insulin Glargine in Patients with Type 2 Diabetes;Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy;2021-01

4. Long-term safety and effectiveness of biosimilar insulin glargine in Japanese patients with diabetes mellitus in routine clinical practice: results of a post-marketing safety study;Current Medical Research and Opinion;2020-04-23

5. Risk of clinically relevant hypoglycaemia in patients with type 2 diabetes self‐titrating insulin glargine U‐100;Diabetes, Obesity and Metabolism;2019-08